Phreesia Stock Price, News & Analysis

Phreesia (NYSE: PHR) reported strong Q2 fiscal 2026 results, marking its first-ever net income positive quarter. The company achieved total revenue of $117.3 million, up 15% year-over-year, with 4,467 healthcare services clients. Key financial highlights include net income of $0.7 million, compared to a $18.0 million loss last year, and Adjusted EBITDA of $22.1 million, up from $6.5 million.

Phreesia announced a definitive agreement to acquire AccessOne, a healthcare receivables financing solutions provider, expected to close in Q3 or early Q4 FY2026. The company maintained its FY2026 revenue outlook of $472-482 million and raised its Adjusted EBITDA guidance to $87-92 million. The acquisition will be financed through cash and a bridge loan.

Phreesia (NYSE: PHR) has announced a definitive agreement to acquire AccessOne for $160 million in cash. AccessOne, a portfolio company of Frontier Growth, is a market leader in healthcare receivables financing solutions, managing a portfolio of approximately $450 million.

The transaction is expected to close during Q3 or early Q4 of Phreesia's fiscal year 2026. The acquisition will be financed through a combination of cash and a new bridge loan. Phreesia anticipates the acquisition to contribute approximately $35 million in annualized revenue and $11 million in annualized Adjusted EBITDA.

AccessOne's platform provides healthcare providers with scalable, compliant tools for improving collections while maintaining patient trust. The acquisition aligns with Phreesia's mission of making healthcare more accessible and is expected to expand their addressable market.

Phreesia (NYSE:PHR) has launched VoiceAI, an innovative AI-powered phone solution designed specifically for healthcare organizations. This new technology integrates with Phreesia's existing patient activation platform to manage high call volumes and streamline patient interactions using natural language processing.

The system features intelligent triage, reliable AI responses based on clinical rules, parallel call handling capacity, and integrated documentation capabilities. VoiceAI handles common healthcare requests including scheduling, prescription refills, and clinical questions 24/7. Early implementation at Urology Associates of Mobile has already demonstrated success, reducing call abandonment rates to zero.

In 2024, Phreesia facilitated approximately 170 million patient visits, representing 1 in 7 healthcare visits across the United States.

Phreesia (NYSE:PHR) and Sesame Workshop have announced a significant 5-year collaboration aimed at improving children's health education and engagement. The partnership will leverage Sesame Street's beloved characters to deliver health-related educational content through Phreesia's digital intake platform, reaching families during medical visits.

Starting October 2025, the initiative will target caregivers of children aged 0-5, providing information about preventive care, vaccinations, routine check-ups, and emotional wellbeing. The collaboration combines Phreesia's reach of one in seven patient visits across the U.S. with Sesame Workshop's 55-year legacy in educational excellence.

Phreesia (NYSE:PHR), a leading patient intake and activation solutions provider, has been recognized on the 2025 Capterra Shortlist in two categories: Patient Engagement and Medical Scheduling. The company maintains a strong 4.3 out of 5 rating on Capterra, based on verified user reviews.

Founded in 2005, Phreesia has demonstrated significant market penetration, facilitating approximately 170 million patient visits in 2024, representing 1 in 7 healthcare visits across the United States. The company's digital solutions portfolio includes patient intake, outreach, education, and other healthcare management tools.

Phreesia (NYSE: PHR), a patient activation solutions provider, has scheduled its fiscal second quarter 2026 financial results announcement for September 4, 2025, after market close. The company will host a conference call at 5:00 PM Eastern Time on the same day to discuss the results.

Founded in 2005, Phreesia serves as a significant player in healthcare technology, facilitating approximately 170 million patient visits in 2024 - representing 1 in 7 healthcare visits across the United States. The company specializes in providing digital solutions for patient intake, outreach, and education to enhance patient experience and healthcare outcomes.

Phreesia (NYSE:PHR) and the COPD Foundation have released a comprehensive study revealing significant gaps in COPD patient care and communication. The research, funded by Verona Pharma, surveyed 1,615 COPD patients in January 2025 through Phreesia's platform.

Key findings show that 43% of patients experience symptoms at least 24 days per month, with 25% reporting daily symptoms. The study highlighted concerning statistics: only 45% of patients have detailed symptom discussions with providers, 20% don't use maintenance medications, and over one-third have limited COPD understanding. The impact is particularly pronounced among Black patients and those aged 45-64 years.

The research emphasizes the critical need for improved patient-provider communication and targeted interventions to enhance COPD care management and patient outcomes.

Phreesia (NYSE:PHR), a leading patient intake and activation solutions provider, has been recognized as the 2025 Top-Rated Vendor for Patient Registration and Intake Solutions by Black Book Research. The recognition is based on surveys from over 11,500 healthcare professionals.

The company's selection highlights significant industry trends, with 89% of respondents reporting that front-end process issues directly impact cash flow and claims, while 77% of providers increased investments in automation tools for patient access, up from 63% in 2023. Phreesia facilitated approximately 170 million patient visits in 2024, representing 1 in 7 visits across the U.S.